Asia Pacific CAR T-Cell Therapy Market Trends for 2026

The Asia Pacific CAR T-cell therapy market size stood at US$ 2.58 billion in 2025, grew to US$ 3.43 billion in 2026, and is forecast to reach US$ 44.01 billion by 2035, expanding at a CAGR of 32.80% from 2026 to 2035.

Key Takeaways

• North America held a major revenue share of 40% in the market in 2025.
• Asia-Pacific is expected to witness the fastest growth at 32.80% CAGR in the coming years.
• By drug type, the axicabtagene ciloleucel segment dominated the market in 2025.
• By drug type, the tisagenlecleucel segment is expected to show lucrative growth during the forecast period.
• By indication, the lymphoma segment held the largest revenue share of the market in 2025.
• By indication, the acute lymphocytic leukemia segment is expected to account for the highest growth in the upcoming years.
• By end-user, the hospitals segment led the market in 2025.
• By end-user, the cancer treatment centers segment is expected to expand rapidly in the forecast years.

CAR T-Cell Therapies Market Overview

The United States and China reported most of the trials on Clinicaltrials.gov while Europe lags behind in terms of CAR T-Cell clinical trials.

CAR T-cell therapies have significant transformative potential in the field of cancer treatment as they harness the power of the immune system to fight cancer. These therapies involve genetically engineering T cells to express a chimeric antigen receptor that specifically targets a tumor antigen, providing a highly personalized approach to cancer treatment.

CAR-T therapy is a type of cell therapy in which immune T cells are modified genetically to attack the cancer cells by means of injecting chimeric antigen receptors. It is also referred to as a "miracle anticancer drug" due to its high response rate. It does, however, have a complicated manufacturing process that includes collecting the patient's T cells at a medical facility and then culturing them in a good manufacturing practice (GMP) facility. The advantages of CAR T-cell therapies over standard medicines include the use of patients’ immune systems to destroy cancer cells, early recovery, and shorter treatment times.

Furthermore, CAR T-cell therapy has a long survival time in the body because it has the ability to recognize and target cancer cells even if cancer recurs. CAR T-cell therapy is primarily used to treat lymphoma, acute lymphocytic leukemia, and multiple myeloma. Due to their numerous advantages over traditional drugs, CAR T-cell therapy products have a high adoption rate, resulting in market growth.

Market Data & Statistics

• The U.S. Food and Drug Administration (FDA) has approved a total of 7 CAR-T cell therapy products as of 2025 that are indicated for different types of blood cancers.
• As of October 10, 2025, a total of 1,703 clinical trials were registered on the clinicaltrials.gov website related to CAR-T cell therapies as interventions.
• Approximately 187,740 were estimated to have been diagnosed with leukemia, lymphoma, and myeloma in the U.S.
• In Australia, more than 19,400 people are diagnosed with blood cancer annually.

Top Companies in CAR T-Cell Therapy Market

• Johnson & Johnson Services, Inc.
• ALLOGENE THERAPEUTICS
• Lonza
• Aurora Biopharma
• Cartesian Therapeutics, Inc.
• Novartis
• Bristol-Myers Squibb company
• Gilead Sciences
• Curocell Inc
• JW Therapeutics

Segments Covered in the Report

By Drug Type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia (CLL)
• Multiple Myeloma (MM)
• Others

By End User

• Hospitals
• Cancer Treatment Centers